Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...

Gilead Sciences’ already dominant position in HIV pre-exposure prophylaxis (PrEP) has been consolidated by a new study showing that its twice-yearly injectable drug was 100% effective in ...

Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Gilead Sciences' already dominant position in HIV pre-exposure prophylaxis (PrEP) could be extended if the FDA approves a new twice-yearly product later this year. The US regulator has started a ...

"Stigma isn't just a social issue; it's a public health crisis." says Marcus Wilson, Gilead Senior Director, U.S. Public Affairs, HIV Advocacy. "It determines the quality of care that people ...

LOS ANGELES, March 25, 2025 /PRNewswire/ -- Revolution Prep, recognized by Time Magazine as one of the World's Top 100 EdTech Companies, is proud to announce its new designation as one of ACT's ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

LOS ANGELES, March 25, 2025 /PRNewswire/ -- Revolution Prep, recognized by Time Magazine as one of the World's Top 100 EdTech Companies, is proud to announce its new designation as one of ACT's ...

I know what it is you really want, and it's neither reams of statistical analysis nor carefully articulated arguments. It's a list of player names, sorted by position and grouped by likely outcome.

Mar. 24—COLUMBUS, Ohio — The 2025 Divisions IV, V, VI and VII girls basketball All-Ohio teams were announced Monday by the Ohio Prep Sports Media Association. The All-Ohio teams are based on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...